32nd Meeting between WHO ERLs, CCs and influenza vaccine manufacturers

Actions and Detail Panel

Sales Ended

Event Information



Online event

Event description
32nd Meeting between WHO ERLs, CCs and influenza vaccine manufacturers.

About this event

This meeting series brings together key stakeholders from the WHO, ERLs, CCs and from industry to discuss current issues surrounding influenza vaccine production. Topics that are covered include virus surveillance, preparation of CVVs, generation and supply of potency testing reagents, review of the current influenza vaccine production campaign and zoonotic influenza as well as other, current items that affect influenza vaccine production and supply.

Please note this 3 day event will take place on Tuesday 13 July, Thursday 15 July and Friday 16 July 2021. This event will not be meeting on Wednesday 14 July 2021.


Day 1 - Tuesday 13 July 2021 10:00-13:00

10:00 Welcome and introductions

10:10 Approval of agenda

10:15 Review of action points from last meeting (unless seperate agenda item)- O Engelhardt

10:20 Review of influenza in the world - CCs

11:20 Seasonal candidate vaccine viruses - NYMC, NIBSC, Seqirus, CBER, China CDC, Sanofi

11:40 Seasonal reagents (questions only) - NIBSC, CBER, TGA, NIID

11:45 Review of southern hemisphere 2021 production campaign - IFPMA (Sam Lee)

Non-Seasonal Influenza

12:15 Update on zoonotic influenza activity, CVVs and reagents - CCs and ERLs

12:40 Summary of day and look ahead

13:00 Close of meeting

Day 2 - Thursday 15 July 2021 10:00-13:00

10:00-11:30 PIVR - OP

PIVR-OP progress and overview

Update from CVV group

Update from Potency testing group

CFWG PIVR activities

11:30 Update from Cross-Functional Working Group (CFWG)

11:50 Update from alternative potency assay taskforce

12:10 Lessons learnt from COVID-19 and influenza

12:30 Any other business, including plans for next meeting and lessons learnt from this meeting

13:00 Close of meeting

Day 3 - Friday 16 July 2021 10:00-13:00

Nagoya protocol and ABS legislation - Impact on influenza vaccines

10:00 Status quo - seasonal influenza viruses and learning from COVID-19 - WHO, CCs

11:00 Proposal for a common approach - Covington*

12:20 Summary and next steps

13:00 Close of meeting

*IFPMA is supporting Covington’s work on the Nagoya Protocol, but is not involved in any other way

Please note programme and timings are subject to change.

Frequently Asked Questions

Access requirements:

If you have any access requirements that we may address to make your participation at our events more enjoyable, please do let us know when registering.

Data Protection

The Medicines and Healthcare products Regulatory Agency will use the information you have provided via the third-party data processor Eventbrite, to facilitate the event, provide you with an acceptable level of service. Any access requirements will be processed internally and will not be shared in any identifiable way with the venue. We will contact you using the information provided for the purpose of this event. By providing the information you agree to the data being processed and stored as outlined.

Privacy Notices

The National Institute for Biological Standards and Control (NIBSC) has its own privacy notice which outlines how we collect and use personal data in accordance with the Data Protection Act 2018 and the General Data Protection Regulation (GDPR) 2016/679.

To find out how we use and manage your personal data please visit the NIBSC Privacy Notice.

Mailing List

To hear about future Medicines and Healthcare products Regulatory Agency events, please click here to be redirected to the Agency's website where you can subscribe to receive event alerts.


Online event

Organiser Medicines & Healthcare products Regulatory Agency

Organiser of 32nd Meeting between WHO ERLs, CCs and influenza vaccine manufacturers

Save This Event

Event Saved